ClinicalTrials.gg
RecruitingNCT06500676Updated Nov 20, 2025

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

A Phase 1/2 interventional study of GFH375 in KRAS G12D Mutations and Advanced Solid Tumors, sponsored by Genfleet Therapeutics (Shanghai) Inc.. Recruiting at 20 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Genfleet Therapeutics (Shanghai) Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
407
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.

02

Conditions studied

  • KRAS G12D Mutations
  • Advanced Solid Tumors
03

In context

Lead sponsor

Genfleet Therapeutics (Shanghai) Inc. is the lead sponsor of 18 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form.
  2. Male or female ≥ 18 years old and ≤75 years old.
  3. performance status of 0-1.
  4. With a of ≥12 weeks.
  5. With or cytologically confirmed advanced or solid tumors harboring KRAS G12D mutation.
  6. Have at least one according to RECIST1.1, and the phase Ia allows no measurable lesion.
  7. Adequate laboratory parameters during the screening period.

Exclusion criteria

Exclusion Criteria:

  1. Active .
  2. Prior treatment with a KRAS G12D inhibitor.
  3. Palliative radiotherapy was completed within 14 days before the first dose.
  4. Have poorly controlled or severe cardiovascular disease.
  5. Subjects with active or active .
  6. Known allergy to the study drug or its components.
  7. Pregnant or lactating women.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
407 participants (estimated)

Study arms

  • Experimental
    GFH375

    Drug: GFH375

Interventions

  • DrugGFH375

    GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

06

What researchers measure

Primary outcomes

  1. Phase Ia:The incidence and severity of AEs and SAEs

    The incidence and severity of AEs and SAEs

    Time frame: 24 months

  2. Phase Ia:The incidence of DLT events

    The incidence of DLT events

    Time frame: 21 days

  3. Phase Ib:The incidence and severity of AEs and SAEs

    The incidence and severity of AEs and SAEs

    Time frame: 24 months

  4. Phase II:Overall response rate (ORR)

    For NSCLC cohort: Assessed by BICR according to RECIST 1.1;For other cohorts: Assessed by investigators according to RECIST 1.1;

    Time frame: 24 months

Secondary outcomes

  1. Plasma concentrations

    Plasma concentrations and PK parameters of GFH375

    Time frame: up to 21 days

  2. Efficacy endpoints

    Duration of response (DoR)

    Time frame: 24 months

  3. Efficacy endpoints

    Disease control rate (DCR)

    Time frame: 24 months

  4. Efficacy endpoints

    Progression free survival (PFS)

    Time frame: 24 months

  5. Efficacy endpoints

    Overall survival (OS)

    Time frame: 24 months

07

Study locations

13 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 15, 2024
StartActual
Jul 9, 2024
Primary completionEst.
Jul 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06500676
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jul 9, 2024
Primary completion
Jul 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 20, 2025

Study contacts

Yolanda Zeng
Contact
yaozeng@genfleet.com
+86 21 6882 1388
Shun Lu, MD
principal investigator · Shanghai Chest Hospital
Aiping Zhou, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12D Inhibitor VS-7375

Start the discussion